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Abstract: BACKGROUND It remains unclear which patients with metastatic germ cell tumours (mGCTs)
need prophylactic anticoagulation to prevent venous thromboembolic events (VTEs). OBJECTIVE To
assess the risk and onset of VTEs stratified by risk factors. DESIGN, SETTING, AND PARTICI-
PANTS This multi-institutional retrospective dataset included mGCT patients treated with first-line
platinum-based chemotherapy. INTERVENTION Patients with prophylactic anticoagulation were ex-
cluded. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS A regression analysis was
performed to select risk factors for VTEs. The simulated number needed to treat (NNT) and the num-
ber needed to harm (NNH) with prophylactic anticoagulation were calculated based on the cumulative
incidences retrieved from this study and hazard rates of recently published trials describing the efficacy
of prophylactic anticoagulation to prevent VTEs and the risk of bleeding events. RESULTS AND LIMI-
TATIONS From 1120 patients, 121 (11%) had a VTE, which occurred prior to chemotherapy in 49 (4%)
and on or after chemotherapy in 72 (6%). Six patients (<1%) had a bleeding event without anticoagu-
lation. After backward regression, the one risk factor for a VTE during or after chemotherapy was the
use of a venous access device. The simulated cumulative VTE incidence from prophylactic anticoagula-
tion for patients on or after chemotherapy would translate into an NNT of 45 (95% confidence interval
[CI] 36-56) and an NNH of 186 (95% CI 87-506). Limitations are mainly related to the retrospective
nature of the study. CONCLUSIONS The mGCTs associated VTEs are most common before and dur-
ing, but not after, chemotherapy. Avoiding venous access device and/or prophylactic anticoagulation
with an acceptable risk-benefit profile may decrease VTE occurring on chemotherapy. PATIENT SUM-
MARY We found that venous thromboembolic events (VTEs) occur rarely after chemotherapy. Based
on experience of prophylactic anticoagulation in other cancers, we conclude that the risk of VTE in men
undergoing chemotherapy for metastatic germ cell tumours can be decreased by thromboprophylaxis with
a reasonable risk-benefit profile and by avoidance of venous access devices.
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Abstract 
Background: It remains unclear which patients with metastatic germ cell tumors 
(mGCT) need prophylactic anticoagulation to prevent venous thromboembolic events 
(VTE).  
Objective To assess risk and onset of VTE stratified by risk factors. 
Design, Setting, and Participants: This multi-institutional retrospective dataset 
included mGCT patients treated with first-line platinum-based chemotherapy.  
Intervention(s): Patients with prophylactic anticoagulation were excluded 
Outcome Measurements and Statistical Analysis Regression analysis was 
performed to select risk factors for VTE. Simulated number needed to treat (NNT) and 
number needed to harm (NNH) with prophylactic anticoagulation were calculated 
based on the cumulative incidences retrieved from this study and hazard rates of 
recently published trials describing the efficacy of prophylactic anticoagulation to 
prevent VTEs and risk of bleeding events. 
Results and Limitations: From 1,120 patients, 121 (11%) had a VTE with 49 (4%) 
occurring prior chemotherapy and 72 (6%) on or after chemotherapy. Six patients 
(<1%) had a bleeding event without anti-coagulation. After backward regression, the 
one risk factor for VTE during or after chemotherapy was the use of a venous access 
device. The simulated cumulative VTE incidence from prophylactic anticoagulation for 
patients on or after chemotherapy would translate into a NNT of 45 (95% confidence 
interval (CI) 36-56) and a NNH of 186 (95% CI 87-506). Limitations are mainly related 
to the retrospective nature of the study. 
Conclusions mGCT associated VTEs are most common before and during but not 
after chemotherapy. Avoiding venous access device and/or prophylactic 
anticoagulation with an acceptable risk:benefit profile may decrease VTE occurring on 
chemotherapy. 
Patient summary We found that VTEs rarely occur after chemotherapy. Based on 
experience of prophylactic anticoagulation in other cancers, we conclude that the risk 
of VTE in men undergoing chemotherapy for mGCT can be decreased by 




In patients with metastatic germ cell tumors (mGCT) venous thromboembolic events 
(VTE) are recognized complications[1]. The most recent ASCO Clinical Practice 
Guideline Update recommends VTE prophylaxis with apixaban, rivaroxaban, or low 
molecular weight heparins (LMWH) to selected high-risk ambulatory patients with 
cancer [2]. This update was based on the findings of recent clinical trials including a 
wide variety of tumour types [3-6]. However, as GCT patients were significantly under-
represented in those trials, the risk:benefit analysis in mGCT to justify prophylactic 
anticoagulation is unknown, especially as there is an associated increased risk of 
bleeding[7]. We aimed to analyse the cumulative incidence and timing of VTE and 
bleeding in mGCT patients with and without known VTE risk factors to identify patients 
most likely to benefit from prophylactic anticoagulation.
Patient and Methods 
This retrospective analysis identified men diagnosed with mGCT from 23 institutions 
in 11 countries treated with first-line platinum-based chemotherapy with curative intent 
between 1998 and 2015. Patients treated with prophylactic anticoagulation, known 
history of coagulopathy, or previous VTE were excluded. Baseline variables included 
age, presence of an indwelling vascular access device, primary tumour site, histology, 
lactate dehydrogenase (LDH), International Germ Cell Cancer Collaborative Group 
(IGCCCG) prognostic group and retroperitoneal lymph node (RPLN) size. Long‐axis 
diameter of RPLN was measured in axial cross section from the pre‐chemotherapy 
CT scan as recommended by the American Joint Committee on Cancer (AJCC) 
staging system and a 3.5cm cut-off was used to dichotomize RPLN size as used 
previously [8]. Khorana score was calculated using body mass index (BMI), serum 
haemoglobin, leukocyte count and platelet count; all patients were scored as having 
testicular cancer [9]. 
Outcomes 
VTE was recorded from 90 days before initial diagnosis up to 180 days after start of 
chemotherapy. In regression analyses the outcome VTE was defined as any deep-
vein thrombosis of the lower or upper limbs, cervical or cerebral veins, pelvic and 
abdominal veins, pulmonary embolism during or after but not before chemotherapy. 
The reason to develop a prediction model for VTE during or after but not before 
chemotherapy was based on the idea that prechemotherapy VTE are already present 
at initial diagnosis and cannot be prevented and were excluded in previous trials [3, 
4]. Similarly, venous access device-related VTEs were not counted as VTE. Bleeding 
was defined as any symptomatic bleeding. 
Statistical Considerations 
Risk factors for VTE were selected using a backward selection procedure. The number 
of factors in the final model was determined based on Akaike information criteria (AIC). 
Odds ratios (OR) and 95% confidence intervals (CI) were provided. The number 
needed to treat (NNT) to prevent one VTE event and number needed to harm (NNH) 
to trigger one bleeding event were simulated as described previously [7]. In brief, the 
HRs from previous trials can be used to estimate the NNT with the following formula 
[10]: 
𝑁𝑁𝑁𝑁𝑁𝑁 = 1
(1 − cumulative incidence)HR– (1 − cumulative incidence) 
As shown in this formula, the NNT is not only influenced by the HR but also 
substantially driven by the cumulative VTE incidence. Because we assumed that VTE 
diagnosed before chemotherapy were identified on staging scans and would not be 
prevented by prophylactic anticoagulation, we used only the cumulative VTE incidence 
during and after chemotherapy for NNT estimations. Regarding the HR for efficacy 
and safety needed for NNT and NNH simulation we assumed the same HR as shown 
in the recent randomised controlled trials CASSINI  [3] and AVERT [4] reporting HRs 
of 0.66 [3] and 0.41[4] for VTE reduction and a HR of 1.96 [3] for increased risk of 
bleeding. Statistical analyses were performed using R version 3.1.3 (R Foundation for 
Statistical Computing, Vienna, Austria). 
Results 
Patient population 
Of 1,218 patients, 19 were excluded due to coagulopathy, history of VTE or bleeding 
(Figure 1). The resulting cohort of 1,199 men originated from 23 institutions in 11 
countries with a median age of 31 years. The majority of patients had testicular non-
seminomatous or mixed GCT and a good prognostic group according to IGCCCG 
(Table 1). 
VTE 
Timing and site of VTE in men without prophylactic anticoagulation 
In the 1120 men without prophylactic anticoagulation (Figure 1), VTE was diagnosed 
in 121 (11%) in the following locations: abdominal and pelvic deep vein thrombosis 
(DVT) in 42 (30%), pulmonary embolism in 39 (28%), lower limb DVT in 25 (18%), 
upper limb DVT in 11 (8%) unknown locations in 2 (1%), internal jugular thrombosis in 
1 (<1%) and cerebral sinus thrombosis in 1 (<1%). Venous access device-related 
VTEs in 17 men were not counted as VTE. Death as a complication from VTE was 
reported in 9 (<1%) patients. VTE was diagnosed before chemotherapy in 49/121 
(40%), during chemotherapy in 56/121 (46%) and after chemotherapy in 16/121 (13%) 
patients (Figure 2). Of the 49 patients with VTE before chemotherapy, 34 patients 
presented with symptomatic VTE, 5 with asymptomatic/incidental VTE and 10 with 
unknown symptoms. 
Cumulative incidence stratified by risk factor 
After removing 49 men with VTE before chemotherapy, the cumulative VTE incidence 
was 72/1071 (7%). The simulated NNT (the number of patients needed to treat with 
prophylactic anticoagulation to prevent one VTE) would be 26 (95% 21-32) or 5(95% 
36-56) depending whether the HR of the CASSINI (0.66) [3] or AVERT (0.41) [4] is 
used (Table 2). In univariable regression analyses the following risk factors were 
associated with VTE during or after chemotherapy: IGCCCG intermediate/poor 
prognostic group, RPLN >3.5cm, use of venous access device, LDH >1.5x upper limit 
of normal. However, the only variable that remained in a multivariable or after 
backward elimination was use of venous access devices (OR 1.8 (95% CI 0.9-3.3) 
(Supplementary table 1). In men without the risk factor venous access device, the 
cumulative VTE incidence was 5% leading to a NNT of 32 or 55 depending on the 
used HR (Table 2). In men with the risk factor venous access device, the cumulative 
VTE incidence was 10% leading to a NNT of 18 or 31. 
 
Bleeding 
Bleeding with full dose anticoagulation 
Full dose anticoagulation because of VTE led to bleeding in 5 men (3.6%, 95%CI 
1.2%-8.3%) including nose in 2, gastrointestinal in 2 and brain in 1. All 5 required 
surgical, endoscopic or endovascular procedures and 2 received blood transfusion. 
Bleeding with prophylactic anticoagulation 
In the 79 men with prophylactic anticoagulation, bleeding occurred in 2 (2.5%, 95% CI 
0.3%-8.8%) in the following sites: abdominal in 1 and brain in 1.  Surgical, endoscopic 
or endovascular procedures were not necessary in these patients; one required blood 
transfusions. 
Bleeding without any anticoagulation 
In 1,120 men on neither prophylactic nor full anticoagulation bleeding was reported in 
6 (0.5%, 95%CI 0.02%-1%) including the following sites: Nose in 2, retroperitoneal in 
1, bladder in 1 and unknown sites in 2. All 6 underwent a surgical, endoscopic or 
endovascular procedure and 3 patients required blood transfusions. The NNH was 
calculated by taking the cumulative bleeding incidence for men not treated with any 
anticoagulation (6/1120, 0.05%), and using the observed HR of 1.96 with DOAC 
prophylaxis (4) to obtain an estimated NNH of 186 (95% CI 87-506) for VTE 
prophylaxis in men with mGCT. 
Discussion 
VTE are common complications in patients with cancer [11]. Although previous reports 
suggested that VTE is associated with shorter progression-free and overall survival 
[12], the VTE mortality in our cohort was <1% which indicates that VTE prophylaxis 
would probably also translate in a small survival benefit. Nevertheless, as the majority 
of patients will be cured after chemotherapy, delay of chemotherapy, long term 
morbidity and  loss of quality of life[13] needs to be prevented in this young patient 
population. According to our simulations the use of thromboprophylaxis only slightly 
increases the risks of bleeding but considerably reduces the risk of VTE during 
chemotherapy. 
 
The recent CASSINI[3] and AVERT[4] trials assessed the risks and benefits of VTE 
prophylaxis in ambulatory patients selected for increased risk of VTE and receiving 
chemotherapy using rivaroxaban or apixaban. Both trials demonstrated a 30-60% risk 
reduction in VTE but increased risk of bleeding, similar to prior findings with LMWH 
which were in unselected patients with low cumulative VTE rate [5, 6]. Based on the 
recent  results, the ASCO Clinical Practice Guideline Update now recommends 
offering VTE prophylaxis with apixaban, rivaroxaban, or LMWH to selected high-risk 
outpatients—those with  a Khorana risk score >2 and low risk of bleeding [2]. However, 
this recommendation is based on clinical trials in which mGCT patients were 
significantly under-represented and we have previously pointed out that disease 
specific risk benefit assessments are needed [7]. Therefore, it remains challenging to 
identify mGCT patients at a sufficiently high risk for VTE to justify prophylactic 
anticoagulation. 
 
Our results confirm that men with mGCT are at a high risk for VTE prior to and until 
the end of chemotherapy. The simulated risks and benefits of prophylactic 
anticoagulation suggest prophylactic anticoagulation prior to and until the end of 
chemotherapy is a reasonable option for men with mGCT as the cumulative VTE 
incidence sharply decreases after chemotherapy (Figure 2). Several prior studies 
described risk factors for VTEs occurring at any time point and did not specific whether 
VTE occurred before, during or after chemotherapy [14-20]. In our cohort this outcome 
definition would have confirmed RPLN >3.5cm and Khorana score as risk factors in 
backward regression (data not shown). However, our analysis was focussed on the 
setting where prophylactic anticoagulation would be able to prevent VTEs. Specifically, 
the VTEs occurring during or after chemotherapy as those occurring before 
chemotherapy were found based on symptoms leading to diagnosis of metastatic 
disease or on staging scans and cannot be prevented by prophylactic anti-coagulation. 
Therefore, RPLN >3.5cm and Khorana score are only risk factors for preoperative 
chemotherapy whereas use of a venous access device remained as the only risk factor 
for VTE during or after chemotherapy. This more precise VTE definition is therefore 
the explanation why previously described risk factors for VTEs in general were not 
selected in our prediction model.  
 
Although prophylactic thromboprophylaxis may only lead to limited absolute risk 
reduction of VTE, it is important to underline that first, a few patients died because of 
VTE and second not only VTEs itself but also complications which may follow can be 
prevented. A direct consequence of VTE include the need for full-anticoagulation 
which is associated with a higher risk for clinically relevant bleeding as up to 10% of 
patients on full-anticoagulation for treatment of VTE [21, 22]. Long term complications 
from VTE include post‐thrombotic syndromes leading to recurring venous leg ulcers 
resulting in chronic pain, decreased mobility, and ongoing medical resource utilization. 
Similarly, pulmonary embolism can impair right ventricular function and pulmonary 
arterial pressure which will not recover in 10–30% of patients, and up to 4% will 
develop  chronic thromboembolic pulmonary hypertension [23]. These complications 
will further decrease quality of life and increase life time costs  to a higher extent then 
simulated previously [24] as many  mGCT patients develop VTEs in their 20s or 30s. 
Also, if a patient requires post chemotherapy surgery, full dose anti-coagulation 
presents a management difficulty. 
 
Two simple interventions prevent VTE and the associated complications: First, the 
restrictive use of venous access devices and second the prescription 
thromboprophylaxis. The latter either consist of oral thromboprophylaxis (apixaban 2.5 
mg bid or rivaroxaban 10 mg q) or subcutaneous LMWH which is for example already 
standard of care in most German institutions [25].  
 
The proportion of men with asymptomatic VTEs before start of treatment merits further 
discussion. Similar to CASSINI[3] in which 5% of all patients had pre-existing proximal 
deep-vein thrombosis before start of treatment,  <1% of our cohort presented with 
asymptomatic and incidentally identified VTEs before starting chemotherapy. Those 
patients should ideally be identified early on and treated with full anticoagulation 
instead of prophylactic anticoagulation. Therefore we suggest to (1) specifically ask 
the radiologist to assess for VTE in the abdomen/pelvis or chest in the staging CT and 
(2) to investigate the value of venous duplex compression ultrasonography of both 
legs as a screening tool to identify lower limb DVT in further studies. 
 
The limitations of our analysis include retrospective data collection subject to selection 
and reporting bias, missing data, heterogeneity in practice patterns, as well as other 
potential confounders of outcome. Given varying follow-up frequency this study might 
not have included all consecutively treated patients at all participating centres and 
missed VTE or bleeding events. Our assumption that the observed HR for VTE risk in 
other clinical trials can be transferred to mGCT patients and that the relative risk would 
remain constant across all risk should ideally be confirmed in randomized trials 
incorporating health economic and quality of life analyses. Similarly, further 
clarification of bleeding risk in this population treated with prophylactic anticoagulation 
needs to be assessed. The bleeding risk estimations are supported by our small 
cohorts on prophylactic anticoagulation and full anticoagulation. However, those are 
maybe overestimations of major bleeding as epistaxis was counted as bleeding event 
and prophylactic anticoagulation was probably given to patients with larger volume 
disease and no standard ascertainment. Nevertheless, it remains unclear whether 
certain subgroups e.g. men with brain metastases or high volume choriocarcinoma 
lung metastases may have a higher risk of bleeding. Because the risk of bleeding is 
crucial for risk benefit assessment further reports of bleeding risk with different 
anticoagulants or risk factors (e.g. thrombocytopenia) are needed. Additionally, cost-
effectiveness analyses to describe the costs of prophylactic anticoagulation as well as 
need and duration of prophylactic anticoagulation after RPLN dissection needs to be 
defined. 
 
The first and most important strength of our analysis is the meticulous definition of 
VTE: as VTEs present before chemotherapy might not be prevented by prophylactic 
anticoagulation we excluded all VTE before chemotherapy in our NNT analyses. We 
also excluded venous access device VTEs as such VTEs often show a more 
favourable outcome compared to other VTEs. The second strength of our analysis is 
the sample size in a rare disease allowing multivariable analysis. Given the low 
incidence of mGCT and rarity of the disease, large prospective randomized trials of 
VTE prophylaxis are currently not planned and are unlikely to be performed. Therefore, 
this analysis presents evidence that prophylactic anticoagulation may have a 
reasonable risk:benefit prophylaxis in all mGCT patients, especially at the time of 
diagnosis and during chemotherapy. 
Figure legends 
Figure 1 Patient flow diagram 
Figure 2 Histogram with density line describing the occurrence of venous 
thromboembolic events (VTE) before, during and after chemotherapy. 
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   United States of America 
   Italy 
   Germany 
   Russia 
   Australia 
   Portugal 













Median age at diagnosis [IQR] 31 [26-38] 
Smoking status 
   Current smoker 
   Ex-smoker 
   Never smoker 






Median Body mass index (kg/m2) [IQR] 25 [22-28] 
Primary site of GCT 
   Gonadal 
   Extra-gonadal  






   Non-seminoma/Mixed  
   Seminoma  






   Good 
   Intermediate 
   Poor 







   BEP 
   EP 
   VIP 
   TIP 
   Other 








Median number of chemotherapy cycles 
[IQR] 
3 [3-4] 
Venous access device 
   Used 
   Not used 






   1 
   2 





   4 




   ≤3.5 cm 
   >3.5cm 






   < 1.5x ULN 
   1.5 - 5x ULN  
   5 - 10x ULN 
   >10x ULN 








Table 1 Baseline characteristics of 1199 patients with metastastic germ cell tumors 
Abbreviations: IGCCCG: International Germ Cell Cancer Collaborative Group; IQR: 
Interquartile range from 25-75% percentiles, LDH: lactate dehydrogenase, RPLN: 
retroperitoneal lymph node, ULN: upper limit of normal 
 Table 2 Number needed to treat based on observed cumulative VTE incidence in 1071 patients without prophylactic anticoagulation 
 All patients  Stratified by risk factor 
   No venous 
access device 
 Venous access 
device 
 Venous access device 
usage missing 
Cumulative VTE incidence* 
95% CI  
 7% (72/1071) 
5-8% 
 5% (31/571) 
4-8% 
 10% (23/234) 
6-14% 
 7% (18/266) 
4-10% 




















Abbreviations: CI: Confidence interval, HR: Hazard ration, NNT: number needed to treat, VTE: venous thromboembolic events, *defined as any deep-vein 
thrombosis of the lower or upper limbs, cervical or cerebral veins, pelvic and abdominal veins, pulmonary embolism during or after but not before 
chemotherapy. Venous access device-related VTEs were not counted as VTE in the regression or further simulation analyses. 
 
Take home message 
The results of this study suggest that all metastatic germ cell cancer patients 
undergoing first-line chemotherapy have an increased risk for VTE, specifically before 
and during chemotherapy. Avoidance of venous access devices and prophylactic 
anticoagulation for patients during chemotherapy with an acceptable risk:benefit 
profile are two simple strategies to possibly decrease VTE risk. 
1218 patients
19 patient with history of bleeding, 
previous VTE or coagulopathy
79 patient on prophylactic anticoagulation




Estimation of VTE onset (Figure 2)
Table 1
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Histogramm and density line for VTE 
occurence over time (truncated data)
 
Variable Univariable regression 
 
 
 Multivariable regression 
 
 
 Model after backwards regression 
 
 
 OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value 
Khorana Score 
   1-2 
   3-4 
1.8 (0.7-4.1) 0.2   
Reference 
 1.1 (0.2-3.8) 
0.9    
RPLN 
   ≤3.5cm 
   >3.5cm 
1.9 (1.1-3.2) 0.02   
Reference 
 1.7 (0.8-3.6) 
0.2   
Reference 
 1.8 (0.9-3.3) 
0.07 
Venous access device 
   No 
   Yes 
1.9 (1.1-3.3) 0.03   
Reference 
2.8 (1.4-5.8) 




Primary site  
   Gonadal 
   Extra-gonadal  
2.0 (0.9-4.2) 0.08   
Reference 
 1.0 (0.2-3.0) 
0.9    
IGCCCG 
  Good/intermediate 
  Poor 
3.0 (1.7-5.8) 0.01   
Reference 
 1.5 (0.6-3.5) 
0.3    
LDH 
   <1.5 ULN 
   ≥1.5 ULN 
1.9 (1.2-3.2) 0.01   
Reference 
0.9 (0.3-2.2) 
0.8    
Supplementary Table 1 Uni- and multivariable regression analysis of risk factors for venous thromboembolic events during or after chemotherapy 
Abbreviations: CI: confidence interval, IGCCCG: International Germ Cell Cancer Collaborative Group, LDH: Lactate Dehydrogenase, OR: odds ratio, RPLN: 
retroperitoneal lymph node, ULN: upper limit of normal 
